| Literature DB >> 31423369 |
Hamza I Butt1, Ahmad Shahbaz2, Haroon Nawaz3, Khurram Butt4.
Abstract
Background To assess the prevalence patterns of isolated/mixed rheumatic valvular lesions and associated risk factors among rheumatic heart disease (RHD) patients undergoing surgical valve replacement. Methods An analytical cross-sectional design was used. Purposive sampling was used to select 87 RHD patients who underwent a first-time valve replacement for mitral, aortic, or both valves between April 1 and October 20, 2016, at Punjab Institute of Cardiology, Lahore, Pakistan. Patients with systemic hypertension, diabetes mellitus type-II, congenital heart defects, coronary artery disease, non-rheumatic valvular degeneration, positive test for hepatitis C, or undergoing concomitant coronary artery bypass graft or a 'redo' valve replacement procedure were excluded. A proforma was used to collect preoperative data on patients' demographics, laboratory investigations, electrocardiogram (ECG), and transthoracic echocardiography reports. Results Age (mean ± S.D.) was 32.79 ± 13.06 years, which was divided into four quartile-based groups. Forty-six (52.9%) cases were males. The majority (56.3%) of patients underwent mitral valve replacement. Mitral regurgitation (MR, 80%) was the most common lesion. Of 71 available ECGs, atrial fibrillation was observed in 46.5% cases. Increasing age group was negatively correlated with MR severity (τc = -0.188, p-value = 0.033) and positively with aortic stenosis (AS) severity (τc = 0.141, p-value = 0.010). No significant elevations were observed for anti-streptolysin O titer, C-reactive protein, and leukocyte count, though the erythrocyte sedimentation rate was abnormally high in 46.94% cases. Conclusions MR was the most common lesion. MR was more severe in younger patients whilst AS was more severe in older cases. There is little evidence of ongoing residual inflammation.Entities:
Keywords: atrial fibrillation; echocardiography; inflammation; rheumatic heart disease; valve lesions; valve replacement
Year: 2019 PMID: 31423369 PMCID: PMC6689495 DOI: 10.7759/cureus.4889
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Demographic and clinical characteristics of patients (n=87)
MVR: mitral valve replacement; AVR: aortic valve replacement; DVR: double valve replacement
| Frequency | Percentage (%) | |
| Age Group (Years) | ||
| 0-21 | 23 | 26.4 |
| 22-31 | 21 | 24.1 |
| 32-41 | 22 | 25.3 |
| ≥ 42 | 21 | 24.1 |
| Age (Mean ±S.D.) | 32.79 ± 13.06 | |
| Gender | ||
| Male | 46 | 52.9 |
| Female | 41 | 47.1 |
| Procedural Class | ||
| Poor | 76 | 87.4 |
| Paying | 11 | 12.6 |
| Procedure Type | ||
| MVR | 49 | 56.3 |
| AVR | 14 | 16.1 |
| DVR | 24 | 27.6 |
| Surgical Outcome | ||
| Discharged | 84 | 96.6 |
| In-hospital Mortality | 3 | 3.4 |
Inflammatory markers
ASO: anti-streptolysin-O; CRP: C-reactive protein; NLR: neutrophil-to-lymphocyte ratio
| Frequency | Percentage (%) | |
| ASO Titer (IU/ml) | ||
| <200 | 69 | 97.18 |
| ≥200 | 2 | 2.82 |
| CRP (mg/l) | ||
| <6 | 55 | 85.94 |
| ≥6 | 9 | 14.06 |
| ESR (mm 1st hour) | ||
| 1-20 | 26 | 53.06 |
| >20 | 23 | 46.94 |
| NLR Groups | ||
| NLR≤1.66 | 29 | 33.33 |
| 1.66 < NLR≤2.12 | 29 | 33.33 |
| NLR>2.12 | 29 | 33.33 |
B-M mode echocardiographic dimensions classified by valve replacement type
SMC denotes significant multiple comparisons, namely, MA=MVR vs. AVR, MD=MVR vs.DVR, and AD=AVR vs. DVR, respectively.
MVR: mitral valve replacement; AVR: aortic valve replacement; DVR: double valve replacement; LVISD: left ventricular internal systolic diameter; LVPWD: left ventricular posterior wall dimensions; LVIDD: left ventricular internal dimension-diastole; LVIDS: left ventricular internal dimension in systole; EF: ejection fractio
| MVR (n=45) | AVR (n=14) | DVR (n=23) | Kruskal Wallis H-Test (2 d.f) | *SMC | ||
| H | p-value | |||||
| LA (mm) | 55.22 ± 1.60 | 38.64 ± 1.25 | 52.17 ± 2.01 | 26.09 | 0.000 | MA, AD |
| LVISD (mm) | 9.84±0.25 | 12.36±0.54 | 10.74±0.37 | 14.43 | 0.001 | MA |
| LVPWD (mm) | 9.69±0.22 | 12.36±0.55 | 10.61±0.33 | 16.06 | 0.000 | MA |
| LVIDD (mm) | 52.31±1.19 | 60.57±3.35 | 58.09±2.51 | 10.51 | 0.005 | MA, MD |
| LVIDS (mm) | 33.56±1.04 | 40.00±2.39 | 40.74±2.14 | 13.31 | 0.001 | MA, MD |
| EF (%) | 59.23±0.77 | 53.29±2.52 | 57.04±1.18 | 4.93 | 0.085 | - |
| LV Mass (g) | 197.76±9.11 | 343.44±30.60 | 267.96±19.16 | 25.33 | 0.000 | MA, MD |
Figure 1Valvular regurgitant lesions (MR, AR, TR)
MR: mitral regurgitation; AR: aortic regurgitation; TR: tricuspid regurgitation
Figure 2Valvular stenotic lesions (AS, MS)
AS: aortic stenosis; MS: mitral stenosis
Tests of association
*significant at α=0.05
AF: atrial fibrillation; MR: mitral regurgitation; AR: aortic regurgitation; TR: tricuspid regurgitation; AS: aortic stenosis; MS: mitral stenosis; PHT: pulmonary hypertension
| Pearson’s χ2 test | ||||||
| AF | Age group | Gender | Procedure Type | |||
| 9.66 (0.022*) | 0.17 (0.676) | 8.67 (0.013*) | ||||
| Fisher’s exact test | ||||||
| MR | AR | TR | MS | AS | PHT | |
| 8.73 (0.107) | 6.89 (0.227) | 11.73 (0.028*) | 2.21 (0.587) | 7.38 (0.017*) | 8.28 (0.075) | |
Tests of Kendall’s rank correlation of valvular lesion severity with age group, PHT, and NLR, respectively
*significant at α=0.05
MR: mitral regurgitation; AR: aortic regurgitation; TR: tricuspid regurgitation; MS: mitral stenosis; TS: tricuspid stenosis
| Age Group | PHT | NLR | |
| MR | -0.19 (0.033*) | 0.27 (0.001*) | 0.03 (0.735) |
| AR | -0.17 (0.058) | -0.23 (0.009*) | -0.11 (0.272) |
| TR | -0.01 (0.885) | 0.43 (0.000*) | 0.16 (0.112) |
| MS | 0.13 (0.106) | 0.32 (0.000*) | 0.14 (0.138) |
| TS | 0.14 (0.010*) | -0.09 (0.075) | 0.06 (0.177) |